Professor John Miller
This research team combines leading expertise in synthetic and medicinal chemistry and cancer biology.
Investigating Fn14 As A Driver Of Breast Cancer Metastasis
Dr Heather Cunliffe
The presence of a protein called Fn14 on the surface of 75% of invasive breast cancers, has been shown to be strongly prognostic for distant metastasis, with the strongest association in HER2/neu positive and Triple Negative breast cancers.
The potential of immunotherapy as a treatment for ER+ve breast cancer
Dr Anita Dunbier
Treatments that stimulate the immune system to attack tumours have revolutionised the treatment of some cancer types.
Targeting growth hormone signal transduction in breast cancer
Dr Jo Perry
One of the most successful strategies for treating breast cancer has been the use of humanised monoclonal antibodies to target secreted growth factors or cell surface receptors whose function has been upregulated in the tumour.
Development of inhibitors of PC-PLC as anticancer therapeutics
Associate Professor David Barker
Many patients with metastatic breast cancer do not respond to conventional chemotherapy and better strategies to treat these patients are urgently needed.
Using CRISPR-Cas9 to predict sensitivity to trastuzumab emtansine
Dr Francis Hunter
Over 3000 diagnoses and 600 deaths are attributable to breast cancer in New Zealand each year.
Targeting HP1 regulated pathways to suppress breast cell invasion
Dr Tracy Hale
Metastasis is the primary cause of death in breast cancer patients as it refractory to current therapies.
Testing a new drug target that promises to impair breast cancer cell growth
Although breast cancer cells have heterogeneous properties, all of them have a high nutritional demand.
Read moreUnderstanding the role of aspirin in breast cancer treatment
Dr Anita Dunbier
Every year, more than 2000 New Zealand women are diagnosed with oestrogen receptor positive breast cancer.
Identifying breast cancer patients with clinically relevant mutations
Associate Professor Logan Walker
Identification of cancer-causing mutations in the breast cancer susceptibility genes, BRCA1 and BRCA2, has well-defined and actionable implications for disease prevention.